Pozen (Nasdaq: POZN) reported a $4.1 million loss for the second quarter. That’s down from a $11.3 million profit posted a year ago due in large part to a $15 million drug milestone payment from GlaxoSmithKline.

For details, see: phx.corporate-ir.net/phoenix.zhtml?c=121701&p=IROL-NRText&t=NewsRelease&id=736267&highlight=